What is Cryo-Cell International, Inc. (CCEL)?

Cryo-Cell International, Inc. (CCEL) is a stock in the Healthcare sector, Medical - Care Facilities industry. View full analysis on Stocks360.

What is the current price of CCEL?

The current price of CCEL is $5.21. Prices are updated in real time on Stocks360.

What is CCEL's price-to-earnings (PE) ratio?

CCEL's trailing twelve-month PE ratio is -23.24, based on current price and earnings per share data available on Stocks360.

What is CCEL's market capitalization?

CCEL's market capitalization is $42,006,407.00, placing it in the small-cap tier.

Cryo-Cell International, Inc. (CCEL)

Stock analysis · AMEX · Healthcare · Medical - Care Facilities

$5.21

Market Cap

$42.01M

PE (TTM)

-23.24

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.59

Day Range

$5.00 – $5.21

52-wk Range

$2.72 – $5.45

Avg Volume

N/A

Volume

12.04K

Cryo-Cell International, Inc. (CCEL) is a publicly traded company in the Healthcare sector. Latest price: $5.21. Market cap $42.01M. Trailing PE -23.24. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $4.51 2026-10-30 · $5.21 (+15.52%)

Earnings

Most Recent

Oct 9, 2026

EPS $0.16 vs est. $0.03

Beat by $0.13

Next Earnings

Feb 26, 2027

EPS estimate $0.05

Proprietary Signals

Signal snapshot temporarily unavailable.

About Cryo-Cell International, Inc.

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-23.24×
P/S (TTM)	1.35×
P/B	-2.56×
PEG	0.06×
P/FCF (TTM)	9.03×
EV / EBITDA	34.42×
EV / Sales	1.32×
Earnings Yield	-6.71%
Free Cash Flow Yield	11.07%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$41.16M
Revenue (TTM)	$31.13M
Net Income (TTM)	-$2.82M
Free Cash Flow (TTM)	$7.35M
Net Debt	-$848.46K
Working Capital	-$2.16M
Gross Margin	77.95%
Operating Margin	0.61%
Net Margin	-9.05%
Return on Equity	15.84%
Return on Invested Capital	0.40%